Press release from Companies
Publicerat: 2025-05-21 11:12:25
Phase Holographic Imaging PHI AB ("PHI" or the "Company") today announces that Patrik Eschricht, former CEO of PHI, will come back as CEO of the Company, effective immediately. He returns to the role he held during 2023 and most of 2024. Ivan Jurkovic, who has been acting CEO since February 2025, will support a smooth transition and will remain on the Board of Directors of PHI.
Patrik Eschricht served as CEO of PHI during 2023 and most of 2024. He also brings senior leadership experience from several fast-growing companies. Eschricht will start his position as CEO of PHI effective immediately. Ivan Jurkovic will remain in the Board of Directors of the Company and will also be available to ensure a smooth transition for Patrik Eschricht.
"The Board of Directors of PHI welcomes Patrik back to the role of CEO. Given his deep understanding of our business and proven leadership, we are confident this transition will ensure continued strategic focus and operational stability", says Goran Dubravcic, Chairman of the Board.
"I am pleased to return as CEO of PHI at a pivotal time in our journey. Having stayed closely engaged with the company, I see a clear path forward to build on the progress we’ve made and to address key growth opportunities in the market. My focus will be on working closely with our leadership team to strengthen our strategic initiatives, enhance operational efficiency, and ensure we continue creating long-term value for our shareholders, customers, and employees.", says Patrik Eschricht, new CEO of PHI.
For more information about PHI, please contact:
Goran Dubravčić, Chairman of the Board
E-mail: ir@phiab.com
Website: www.phiab.com
About PHI
Phase Holographic Imaging (PHI) is a medical technology company that develops and markets its non-invasive time-lapse imaging instruments for long-term quantitative analysis of living cells. The foundation of PHI's current commercial HoloMonitor® products is Quantitative Phase Imaging (QPI) technology - an innovative approach to cell quality evaluation. QPI offers detailed analysis of cell characteristics without harming the cells, avoiding the limitations of traditional measurement methods. PHI is actively focusing on business development to expand from pre-clinical research to the clinical market and the emerging regenerative medicine field. PHI envisions transforming live cell analysis and establishing QPI as a standard for cell quality control, making future cell therapies safe, affordable, and accessible for patients. PHI is based in Lund, Sweden, Boston, MA and Winston-Salem, NC.
